Search research articles
Contact Us
Filters
Showing results (61-70 of 67) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 67 results.
Wiener Medizinische Wochenschrift (1946)
|
January 1, 1991
[Alzheimer dementia. A clinical long-term study with quantitative neuropathology]
P Fischer, H Lassmann, K Jellinger, et al.
Neuroscience
|
January 1, 1992
Synaptic pathology in Alzheimer's disease: immunological data for markers of synaptic and large dense-core vesicles
H Lassmann, R Weiler, P Fischer, et al.
The Mount Sinai Journal of Medicine, New York
|
January 1, 1988
Biochemical fundamentals of Parkinson's disease
P Riederer, W D Rausch, B Schmidt, et al.
European Journal of Clinical Pharmacology
|
January 1, 1992
Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued
H Przuntek, D Welzel, E Blümner, et al.
Neuroscience Letters
|
June 16, 2000
Human post-mortem striatal alpha4beta2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome
N Durany, R Zöchling, K W Boissl, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)
|
January 1, 1996
Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study
H Przuntek, D Welzel, M Gerlach, et al.
Neurobiology of Aging
|
January 18, 2005
Oxidative stress related markers in the "VITA" and the centenarian projects
E Grünblatt, R Schlösser, P Fischer, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 67) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 67 results.
Wiener Medizinische Wochenschrift (1946)
|
January 1, 1991
[Alzheimer dementia. A clinical long-term study with quantitative neuropathology]
P Fischer, H Lassmann, K Jellinger, et al.
Neuroscience
|
January 1, 1992
Synaptic pathology in Alzheimer's disease: immunological data for markers of synaptic and large dense-core vesicles
H Lassmann, R Weiler, P Fischer, et al.
The Mount Sinai Journal of Medicine, New York
|
January 1, 1988
Biochemical fundamentals of Parkinson's disease
P Riederer, W D Rausch, B Schmidt, et al.
European Journal of Clinical Pharmacology
|
January 1, 1992
Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued
H Przuntek, D Welzel, E Blümner, et al.
Neuroscience Letters
|
June 16, 2000
Human post-mortem striatal alpha4beta2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome
N Durany, R Zöchling, K W Boissl, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)
|
January 1, 1996
Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study
H Przuntek, D Welzel, M Gerlach, et al.
Neurobiology of Aging
|
January 18, 2005
Oxidative stress related markers in the "VITA" and the centenarian projects
E Grünblatt, R Schlösser, P Fischer, et al.
Page
of 7